

REF			SYSTEM
09318747190	09318747500	300	cobas e 402 cobas e 801

## English

### System information

Short name	ACN (application code number)
PCTX	10241

### Intended use

Immunoassay for the in vitro quantitative determination of procalcitonin (PCT) in human serum and plasma. PCT is a marker of host response to bacterial infection. The Elecsys BRAHMS PCT assay is indicated as an aid to be used in conjunction with clinical evaluation for:

- the early detection of clinically relevant bacterial infections
- the assessment of the degree of severity and the prognosis of the outcome of systemic bacterial infection, sepsis, and septic shock
- identifying patients that benefit from antibiotic treatment
- monitoring of antibiotic therapy
- assessing the success of antibiotic therapy

in patients with suspected or confirmed bacterial infection.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on **cobas e** immunoassay analyzers.

### Summary

Sepsis presents a tremendous challenge to the healthcare system with an in-hospital mortality rate of up to 26%.<sup>1</sup> The treatment goal in sepsis is to administer effective antimicrobial therapy as soon as possible as earlier recognition of sepsis and intervention improve patient outcome.<sup>2,3</sup> Lower respiratory tract infections (LRTIs) are a leading cause of sepsis and account for approximately 16% of global sepsis-related deaths.<sup>4</sup> Respiratory tract infections (RTIs) are a common cause of antibiotic overtreatment with antibiotics prescribed for approximately 50-60% of patients with suspected acute RTIs<sup>5,6,7</sup> and up to 70% of patients with suspected LRTIs, despite the vast majority having a viral etiology.<sup>8,9,10</sup> This inappropriate use of antibiotics is believed to be a primary cause of the spread of antibiotic-resistant bacteria.<sup>11</sup> Antibiotic stewardship programs, involving promotion of the appropriate administration of antibiotics, are essential to combat the increase of antibiotic-resistant microorganisms.

PCT is a precursor protein of the hormone calcitonin produced by parafollicular cells (C cells) of the thyroid and neuroendocrine cells of the lung and the intestine.<sup>12,13</sup> PCT is undetectable in the blood of healthy individuals, but is produced ubiquitously in response to endotoxin or mediators released following bacterial infections.<sup>14,15</sup>

PCT serum concentrations are elevated in clinically relevant bacterial infections and can further increase correlating to the severity of infection.<sup>14,16,17,18</sup> Successful control of the underlying bacterial infection by the host immune system or antibiotic therapy results in a decrease of PCT concentration, with a half-life of 24 hours.<sup>14,16,17</sup> The measurable decline of PCT levels can be used to guide the discontinuation of antibiotic therapy.<sup>19</sup>

Depending on the clinical setting, PCT cut-off values can be used to guide antibiotic therapy decisions alongside other clinical and laboratory parameters.<sup>20</sup> In the low and moderate acuity setting (primary care/emergency department/medical ward), PCT concentrations  $\leq 0.25$   $\mu\text{g/L}$  aid in identification of patients in which bacterial infection is unlikely and antibiotic therapy should be discouraged.<sup>19</sup> PCT concentrations  $> 0.25$   $\mu\text{g/L}$  aid in identification of patients with a probable bacterial infection for which antibiotic therapy is recommended.

Several randomized controlled trials and meta-analyses have demonstrated that the use of PCT-guided initiation or discontinuation of antibiotic therapy in patients with acute RTIs significantly reduces antibiotic consumption without compromising patient outcome.<sup>21,22,23,24,25,26</sup> Safe reduction of antibiotic consumption through PCT guidance was confirmed in routine clinical practice without increased risk of complications.<sup>27</sup>

The utility of PCT for guiding antibiotic therapy decisions has similarly been shown for sepsis with beneficial patient outcome.<sup>28,29,30,31,32,33</sup> A patient-level meta-analysis confirmed that PCT guidance can also be used in

patients with impaired kidney function, for which PCT use was associated with shorter antibiotic treatment duration and lower mortality rates.<sup>33</sup>

The use of PCT to guide antibiotic therapy duration is recommended in International guidelines. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2018 guidelines support the use of diagnostic tests, such as PCT, as part of sepsis management to guide antibiotic duration and dosing.<sup>34</sup> The 2011 European Respiratory Society (ERS) support the use of PCT to guide shorter treatment duration in patients with community acquired pneumonia.<sup>35</sup> PCT is also listed in the World Health Organization Model List of Essential In Vitro Diagnostics to guide antibiotic therapy or discontinuation in sepsis and LRTI (for use only in tertiary care facilities and above).<sup>36</sup>

### Test principle

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: Antigen in the sample (18  $\mu\text{L}$ ), a biotinylated monoclonal PCT-specific antibody, and a monoclonal PCT-specific antibody labeled with a ruthenium complex<sup>a)</sup> react to form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell II M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the **cobas** link.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex ( $\text{Ru}(\text{bpy})_3^{2+}$ )

### Reagents - working solutions

The **cobas e** pack (M, R1, R2) is labeled as PCTX.

M Streptavidin-coated microparticles, 1 bottle, 12.4 mL:  
Streptavidin-coated microparticles 0.72 mg/mL; preservative.

R1 Anti-PCT-Ab~biotin, 1 bottle, 18.8 mL:  
Biotinylated monoclonal anti-PCT antibody (mouse) 2.0  $\mu\text{g/mL}$ ;  
phosphate buffer 95 mmol/L, pH 7.5; preservative.

R2 Anti-PCT-Ab~ $\text{Ru}(\text{bpy})_3^{2+}$ , 1 bottle, 18.8 mL:  
Monoclonal anti-PCT antibody (mouse) labeled with ruthenium  
complex 5.6  $\mu\text{g/mL}$ ; phosphate buffer 95 mmol/L, pH 7.5;  
preservative.

PCT Cal1 PCT calibrator 1 (lyophilized), 1 bottle for 4 mL:  
PCT (recombinant) approximately 0.10 ng/mL in a human  
serum matrix; preservative.

PCT Cal2 PCT calibrator 2 (lyophilized), 1 bottle for 4 mL:  
PCT (recombinant) approximately 54 ng/mL in a human  
serum matrix; preservative.

PC PCT1 PreciControl PCT 1 (lyophilized), 2 bottles each for 4 mL:  
PCT (recombinant) approximately 0.50 ng/mL in a human  
serum matrix; preservative.

PC PCT2 PreciControl PCT 2 (lyophilized), 2 bottles each for 4 mL:  
PCT (recombinant) approximately 10 ng/mL in a human  
serum matrix; preservative.

Calibrators: The exact lot-specific calibrator values are available via the **cobas** link.

Controls: The exact lot-specific target values and ranges are available via the **cobas** link.

# Elecsys BRAHMS PCT

## Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:



### Warning

H317 May cause an allergic skin reaction.

H412 Harmful to aquatic life with long lasting effects.

### Prevention:

P261 Avoid breathing dust.

P273 Avoid release to the environment.

P280 Wear protective gloves.

### Response:

P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

### Disposal:

P501 Dispose of contents/container to an approved waste disposal plant.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

All human material should be considered potentially infectious. All products derived from human blood are prepared exclusively from the blood of donors tested individually and shown to be free from HBsAg and antibodies to HCV and HIV. The testing methods use assays that have been approved or cleared by the FDA or that are in compliance with the legal rules of the European Union (IVDR 2017/746/EU, IVDD 98/79/EC, Annex II, List A). However, as no testing method can rule out the potential risk of infection with absolute certainty, the material should be handled with the same level of care as a patient specimen. In the event of exposure, the directives of the responsible health authorities should be followed.<sup>37,38</sup>

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

### Reagent handling

The reagents (M, R1, R2) in the kit are ready-for-use and are supplied in **cobas e** packs.

#### Calibrators and controls:

Carefully dissolve the contents of 1 bottle by adding exactly 4.0 mL of distilled or deionized water and allow to stand closed for 15 minutes to reconstitute. Mix carefully, avoiding foam formation. Transfer the reconstituted calibrators/controls into empty labeled snap-cap bottles.

Unless the entire volume is necessary for calibration and quality control on the analyzer, transfer aliquots of the freshly reconstituted calibrators and controls into empty snap-cap bottles (CalSet Vials/ControlSet Vials). Attach the supplied labels to these additional bottles. Store the aliquots at -20 °C (± 5 °C) for later use. Perform **only one** calibration or control procedure per aliquot.

**Note:** Do not combine bottles from different lots. Use only control bottles out of one lot with each other.

All information required for correct operation is available via the **cobas** link.

### Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the **cobas e** pack **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability of the <b>cobas e</b> pack:	
unopened at 2-8 °C	up to the stated expiration date
on the analyzers	16 weeks

The lyophilized calibrators and controls are stable up to the stated expiration date.

Stability of the reconstituted calibrators/controls:	
at -20 °C (± 5 °C)	3 months (freeze only once)
on the analyzers at 20-25 °C	2 hours (use only once)

Store the calibrators and controls **upright** in order to prevent the solution from adhering to the snap-cap.

### Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, K<sub>2</sub>-EDTA and K<sub>3</sub>-EDTA plasma.

Plasma tubes containing separating gel can be used.

Criterion: Slope 0.9-1.1 + intercept within  $\pm 0.06$  ng/mL + coefficient of correlation  $\geq 0.95$ .

Stable for 24 hours at 20-25 °C, 48 hours at 2-8 °C, 13 months at -20 °C (± 5 °C). Freeze only once.

Frozen samples can lead to a lower recovery of up to 8 %.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use samples and controls stabilized with azide.

Ensure the samples and calibrators are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples and calibrators on the analyzers should be analyzed/measured within 2 hours.

### Materials provided

See "Reagents – working solutions" section for reagents.

- 2 x 8 bottle labels (calibrators)
- 2 x 14 bottle labels (controls)
- 6 empty labeled snap-cap bottles

### Materials required (but not provided)

- [REF] 11776576322, CalSet Vials, 2 x 56 empty snap-cap bottles
- [REF] 03142949122, ControlSet Vials, 2 x 56 empty snap-cap bottles
- General laboratory equipment

- **cobas e** analyzer

Additional materials for **cobas e** 402 and **cobas e** 801 analyzers:

- [REF] 06908799190, ProCell II M, 2 x 2 L system solution
- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF] 07485409001, Reservoir Cup, 8 cups to supply ProCell II M and CleanCell M
- [REF] 05694302001, Assay Tip/Assay Cup tray, 6 magazines x 6 magazine stacks x 105 assay tips and 105 assay cups, 3 wasteliners

# Elecsys BRAHMS PCT



- [REF] 07485425001, Liquid Flow Cleaning Cup, 2 adaptor cups to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning Detection Unit
- [REF] 07485433001, PreWash Liquid Flow Cleaning Cup, 1 adaptor cup to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning PreWash Unit
- [REF] 11298500316, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

## Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Place the cooled (stored at 2-8 °C) **cobas e** pack on the reagent manager. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the **cobas e** pack.

### Calibrators:

Place the reconstituted calibrators (in the system-compatible bottles with barcoded labels) in the sample zone.

Read in all the information necessary for calibrating the assay.

After calibration has been performed, discard the calibrators.

### Controls:

Place the reconstituted controls in the sample zone.

After the control procedure has been performed, discard the controls.

## Calibration

Traceability: This method has been standardized against the BRAHMS PCT LIA assay.

The predefined master curve is adapted to the analyzer using PCT Cal1 and PCT Cal2.

**Calibration frequency:** Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the **cobas e** pack was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 12 weeks when using the same reagent lot
- after 28 days when using the same **cobas e** pack on the analyzer
- as required: e.g. quality control findings outside the defined limits

## Quality control

Use PC PCT 1 and PC PCT 2 or other suitable controls for routine quality control procedures.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per **cobas e** pack, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

**Note:** When using 2 reagent kits with different lots in the same run, the controls will be measured with both reagent lots. Use only control values measured with the corresponding lots.

## Calculation

The analyzer automatically calculates the analyte concentration of each sample in ng/mL.

## Limitations - interference

The effect of the following endogenous substances and pharmaceutical compounds on assay performance was tested. Interferences were tested up to the listed concentrations and no impact on results was observed.

## Endogenous substances

Compound	Concentration tested
Bilirubin	≤ 685 μmol/L or ≤ 40 mg/dL
Hemoglobin	≤ 0.559 mmol/L or ≤ 900 mg/dL
Intralipid	≤ 1500 mg/dL
Biotin	≤ 4912 nmol/L or ≤ 1200 ng/mL
Rheumatoid factors	≤ 1200 IU/mL

Criterion: For concentrations ≤ 0.1 ng/mL the deviation is ≤ 0.015 ng/mL. For concentrations > 0.1 ng/mL the deviation is ≤ 15 %.

There is no high-dose hook effect at PCT concentrations up to 1000 ng/mL.

## Pharmaceutical substances

In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the assay was found.

In addition, the following special therapeutic substances were tested. No interference with the assay was found.

## Special therapeutic substances

Drug	Concentration tested mg/L
Cefotaxime	≤ 900
Dobutamine	≤ 11.2
Dopamine	≤ 130
Furosemide	≤ 20
Imipenem	≤ 1180
Noradrenaline	≤ 2.0
Vancomycin	≤ 3500

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

PCT levels can be increased in certain situations without infectious origin. These include, but are not limited to:<sup>39</sup>

- prolonged or severe cardiogenic shock
- prolonged severe organ perfusion anomalies
- small cell lung cancer or medullary C-cell carcinoma of the thyroid
- early after major trauma, major surgical intervention, severe burns
- treatments which stimulate the release of pro-inflammatory cytokines
- neonates (< 48 hours after birth)<sup>40</sup>

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

## Limits and ranges

### Measuring range

0.02-100 ng/mL (defined by the Limit of Detection and the maximum of the master curve). Values below the Limit of Detection are reported as < 0.02 ng/mL. Values above the measuring range are reported as > 100 ng/mL.

### Lower limits of measurement

*Limit of Blank, Limit of Detection and Limit of Quantitation*

Limit of Blank = 0.015 ng/mL

Limit of Detection = 0.02 ng/mL

Limit of Quantitation = 0.06 ng/mL

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95<sup>th</sup> percentile value from n ≥ 60 measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

# Elecsys BRAHMS PCT

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with an intermediate precision CV of  $\leq 20\%$ .

## Dilution

Samples with PCT concentrations above the measuring range can be diluted manually with PCT negative human serum or plasma. The recommended dilution is 1:4. The concentration of the diluted sample must be  $\geq 20$  ng/mL. After manual dilution, multiply the result by the dilution factor.

## Expected values

### Reference range

A study performed with the Elecsys BRAHMS PCT assay using 492 samples from apparently healthy males (245) and females (247) revealed the following normal value: 0.046 ng/mL (95<sup>th</sup> percentile).

### Clinical cutoff

Note: The cutoffs indicated below may vary according to the clinical situation.

PCT serum concentrations are elevated in clinically relevant bacterial infections and continue to rise with the increasing severity of the disease. However, as an expression of individually different immune responses and different clinical situations, the same focus of infection may be associated with varying individual elevations in PCT concentrations. Therefore, clinicians should use the PCT results in conjunction with the patient's other laboratory findings and clinical signs, and interpret the concrete values in the context of the patient's clinical situation. The reference ranges are therefore given for orientational purpose only.

Diagnosis of systemic bacterial infection/sepsis\*<sup>17,18,41</sup>

\*SIRS, Sepsis, Severe Sepsis, and Septic Shock were categorized according to the criteria of the consensus conference of the American College of Chest Physicians/Society of Critical Care Medicine<sup>42</sup>

ng/mL PCT	Analysis
< 0.5	Local bacterial infection is possible. Systemic infection (sepsis) is unlikely. Low risk for progression to severe systemic infection (severe sepsis). <b>IMPORTANT:</b> PCT levels < 0.5 ng/mL do not exclude an infection, because localized infections (without systemic signs) may be associated with such low levels. If the PCT measurement is done very early after bacterial insult (< 6 hours), values may still be low. In this case, PCT should be re-assessed 6-24 hours later.
$\geq 0.5$ to < 2	Systemic infection (sepsis) is possible, but various conditions are known to induce PCT as well (see below). Moderate risk for progression to severe systemic infection (severe sepsis). The patient should be closely monitored both clinically and by re-assessing PCT within 6-24 hours.
$\geq 2$ to < 10	Systemic infection (sepsis) is likely, unless other causes are known. High risk for progression to severe systemic infection (severe sepsis).
$\geq 10$	Important systemic inflammatory response, almost exclusively due to severe bacterial sepsis or septic shock. High likelihood of severe sepsis or septic shock.

## Differential diagnosis of Lower Respiratory Tract Infections<sup>21</sup>

ng/mL PCT	Analysis
< 0.1	Indicates absence of bacterial infection. Use of antibiotics strongly discouraged, also in the presence of impaired pulmonary reserve in AECOPD.

ng/mL PCT	Analysis
0.1 to 0.25	Bacterial infection unlikely. The use of antibiotics is discouraged.
> 0.25 to 0.5	Bacterial infection is likely. Antibiotic treatment is encouraged.
> 0.5	Suggestive of the presence of bacterial infection. Antibiotic treatment is strongly encouraged.

Antibiotic guidance in sepsis<sup>43</sup> and LRTI<sup>22</sup>

Antibiotic therapy should be considered regardless of PCT result if the patient is clinically unstable, is at high risk for adverse outcome, has strong evidence of bacterial pathogen, or the clinical context indicates antibiotic therapy is warranted. If antibiotics are withheld, reassess if symptoms persist/worsen and/or repeat PCT measurement within 6-24 hours.

In order to assess treatment success and to support a decision to discontinue antibiotic therapy, follow up samples should be tested once every 1-2 days, based upon physician discretion taking into account the patients' evolution and progress. Antibiotic therapy may be adjusted using the discontinuation formula below:

- PCT<sub>Peak</sub>: Highest observed PCT concentration
- PCT<sub>Current</sub>: Most recent PCT concentration
- $\Delta$ PCT: Change in PCT concentration

$\Delta$ PCT: Calculate by using the following equation:

$$\Delta\text{PCT} = \frac{\text{PCT}_{\text{Peak}} - \text{PCT}_{\text{Current}}}{\text{PCT}_{\text{Peak}}} \times 100$$

Antibiotic therapy may be discontinued if the  $\Delta$ PCT > 80 % or if the PCT<sub>Current</sub> is:

- $\leq 0.25$  ng/mL for LRTI patients
- $\leq 0.5$  ng/mL for suspected or confirmed septic patients

Antibiotic therapy may be continued based upon other clinical findings, such as:

- apparent progression on chest x-ray or ongoing/increasing toxicity for LRTI patients or
- failure to control a local infection, or ongoing physiologic instability for patients with suspected or confirmed sepsis.

If clinical picture has not improved and PCT remains high, re-evaluate and consider treatment failure or other causes.

## Recommendations for laboratory reports

It is suggested to report the numerical PCT values (individual or paired). For paired PCT values the report should also indicate if the  $\Delta$ PCT(%) was  $\leq 80\%$  or  $> 80\%$ . The laboratory report should include a reference or a link to the Elecsys BRAHMS PCT assay Method Sheet for a guided interpretation of the test results.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

## Clinical performance

Clinical studies were conducted on samples from 283 ICU patients. The patients were classified into categories based on the ACCP/SCCM (American College of Chest Physicians/Society of Critical Care Medicine) consensus criteria on their first day of ICU admission: SIRS (systemic inflammatory response syndrome), sepsis, severe sepsis and septic shock.<sup>44</sup>

The PCT values of the patients with SIRS (n = 95) or sepsis (n = 71) compared to patients with severe sepsis (n = 60) or septic shock (n = 57) were as follows:

Results with a cutoff at 0.5 ng/mL

Elecsys BRAHMS PCT	Clinical classification		
	SIRS	Severe sepsis/ septic shock	Total
< 0.5 ng/mL	63	5	68

# Elecsys BRAHMS PCT

Elecsys BRAHMS PCT	Clinical classification		Total
	SIRS	Severe sepsis/ septic shock	
≥ 0.5 ng/mL	32	112	144
Total	95	117	212

Based on the above data the sensitivity was 96 %, the specificity 66 %, the positive predictive value 78 % and the negative predictive value 93 %.

Elecsys BRAHMS PCT	Clinical classification		Total
	SIRS	Sepsis	
< 0.5 ng/mL	63	25	88
≥ 0.5 ng/mL	32	46	78
Total	95	71	166

Based on the above data the sensitivity was 65 %, the specificity 66 %, the positive predictive value 59 % and the negative predictive value 72 %.

Results with a cut-off at 2 ng/mL

Elecsys BRAHMS PCT	Clinical classification		Total
	SIRS	Severe sepsis/ septic shock	
< 2 ng/mL	88	18	106
≥ 2 ng/mL	7	99	106
Total	95	117	212

Based on the above data the sensitivity was 85 %, the specificity 93 %, the positive predictive value 93 % and the negative predictive value 82 %.

Elecsys BRAHMS PCT	Clinical classification		Total
	SIRS	Sepsis	
< 2 ng/mL	88	55	143
≥ 2 ng/mL	7	16	23
Total	95	71	166

Based on the above data the sensitivity was 23 %, the specificity 93 %, the positive predictive value 70 % and the negative predictive value 62 %.

## Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

## Precision

Precision was determined using Elecsys reagents, pooled human sera and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days (n = 84). The following results were obtained:

cobas e 402 and cobas e 801 analyzers					
Sample	Mean ng/mL	Repeatability		Intermediate precision	
		SD ng/mL	CV %	SD ng/mL	CV %
Human serum 1	0.0557	0.00209	3.8	0.00253	4.5
Human serum 2	0.490	0.00783	1.6	0.0120	2.4
Human serum 3	1.69	0.0245	1.5	0.0424	2.5
Human serum 4	31.4	0.421	1.3	0.952	3.0
Human serum 5	91.4	1.56	1.7	2.47	2.7
PreciControl PCT1	0.469	0.00674	1.4	0.0113	2.4
PreciControl PCT2	9.68	0.134	1.4	0.245	2.5

## Method comparison

a) A comparison of the Elecsys BRAHMS PCT assay, [REF] 08828679190 / 08828679200 / 09318747190 / 09318747200 (cobas e 801 analyzer; y),

with the Elecsys BRAHMS PCT assay, [REF] 07301715190 / 07301715200 (cobas e 801 analyzer; x), using humannative serum gave the following correlations (ng/mL):

Number of samples measured: 153

Passing/Bablok<sup>45</sup> Linear regression  
 $y = 1.010x - 0.000418$   $y = 1.000x + 0.0622$   
 $r = 0.994$   $r = 1.00$

The sample concentrations were between 0.0368 and 93.6 ng/mL.

b) A comparison of the Elecsys BRAHMS PCT assay, [REF] 08828679190, 08828679200, 09318747190, 09318747200 (cobas e 402 analyzer; y), with the Elecsys BRAHMS PCT assay, [REF] 08828679190 / 08828679200 (cobas e 801 analyzer; x), gave the following correlations (ng/mL):

Number of samples measured: 135

Passing/Bablok<sup>45</sup> Linear regression  
 $y = 0.989x - 0.00304$   $y = 0.990x - 0.0191$   
 $r = 0.992$   $r = 1.00$

The sample concentrations were between 0.104 and 99.1 ng/mL.

## Analytical specificity

The Elecsys BRAHMS PCT assay did not show any significant cross reactions with the following substances, when tested with PCT concentrations of approximately 0.4 ng/mL and 1.5 ng/mL:

Substances	Maximum tested concentration ng/mL
Human katacalcin	30
Human calcitonin	10
Salmon calcitonin	30000
Eel calcitonin	30000
Human alpha-CGRP <sup>b)</sup>	10000
Human beta-CGRP	10000

b) Calcitonin Gene-Related Peptide

## Concordance with BRAHMS PCT LIA/BRAHMS PCT sensitive KRYPTOR

A comparison study was performed with the Elecsys BRAHMS PCT assay and the BRAHMS PCT LIA. Cutoff values of 0.5 ng/mL and 2 ng/mL have been evaluated.

Elecsys BRAHMS PCT	BRAHMS PCT LIA		Total
	< 0.5 ng/mL	≥ 0.5 ng/mL	
< 0.5 ng/mL	104	49	153
≥ 0.5 ng/mL	6	370	376
Total	110	419	529

Elecsys BRAHMS PCT	BRAHMS PCT LIA		Total
	< 2 ng/mL	≥ 2 ng/mL	
< 2 ng/mL	266	10	276
≥ 2 ng/mL	11	242	253
Total	277	252	529

The concordance between both assays was 90 % at the cutoff value of 0.5 ng/mL and 96 % at the cutoff-value of 2 ng/mL.

The Elecsys BRAHMS PCT assay was also compared to the BRAHMS PCT sensitive KRYPTOR. Cutoff values of 0.5 ng/mL and 2 ng/mL have been evaluated.

Elecsys BRAHMS PCT	BRAHMS PCT sensitive KRYPTOR		Total
	< 0.5 ng/mL	≥ 0.5 ng/mL	
< 0.5 ng/mL	183	20	203

# Elecsys BRAHMS PCT

Elecsys BRAHMS PCT	BRAHMS PCT sensitive KRYPTOR		Total
	< 0.5 ng/mL	≥ 0.5 ng/mL	
≥ 0.5 ng/mL	2	392	394
Total	185	412	597

Elecsys BRAHMS PCT	BRAHMS PCT sensitive KRYPTOR		Total
	< 2 ng/mL	≥ 2 ng/mL	
< 2 ng/mL	312	24	336
≥ 2 ng/mL	1	260	261
Total	313	284	597

The concordance between both assays was 96 % at the cutoff value of 0.5 ng/mL and 96 % at the cutoff-value of 2 ng/mL.

## References

- Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. *Am J Respir Crit Care Med* 2016;193:259-272.
- Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit Care Med* 2006;34:1589-1596.
- Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Crit Care Med* 2017;45:486-552.
- Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. *Lancet* 2020;395:200-211.
- Sun BZ, Chaitoff A, Hu B, et al. Empathy, burnout, and antibiotic prescribing for acute respiratory infections: a cross-sectional primary care study in the US. *Br J Gen Pract* 2017;67:e565-e571.
- Gidengil CA, Mehrotra A, Beach S, et al. What drives variation in antibiotic prescribing for acute respiratory infections? *J Gen Intern Med* 2016;31:918-924.
- McCullough AR, Pollack AJ, Plejdrup Hansen M, et al. Antibiotics for acute respiratory infections in general practice: comparison of prescribing rates with guideline recommendations. *Med J Aust* 2017;207:65-69.
- Little P, Stuart B, Smith S, et al. Antibiotic prescription strategies and adverse outcome for uncomplicated lower respiratory tract infections: prospective cough complication cohort (3C) study. *BMJ* 2017;357:j2148.
- Kraus EM, Pelzl S, Szecsenyi J, et al. Antibiotic prescribing for acute lower respiratory tract infections (LRTI) - guideline adherence in the German primary care setting: An analysis of routine data. *PLoS ONE* 2017;12:e0174584.
- Gotta V, Baumann P, Ritz N, et al. Drivers of antibiotic prescribing in children and adolescents with febrile lower respiratory tract infections. *PLoS ONE* 2017;12:e0185197.
- Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. *Ther Adv Drug Saf* 2014;5:229-241.
- Becker KL, Nylén ES, White JC, et al. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. *J Clin Endocrinol Metab* 2004;89:1512-1525.
- Maruna P, Nedelníková K, Gürlich R. Physiology and genetics of procalcitonin. *Physiol Res* 2000;49 Suppl 1:S57-61.
- Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. *BMC Med* 2011;9:107.
- Rowther FB, Rodrigues CS, Deshmukh MS, et al. Prospective comparison of eubacterial PCR and measurement of procalcitonin levels with blood culture for diagnosing septicemia in intensive care unit patients. *J Clin Microbiol* 2009;47:2964-2969.
- Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. *J Clin Endocrinol Metab* 1994;79:1605-1608.
- Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. *Am J Respir Crit Care Med* 2001;164:396-402.
- Müller B, Becker KL, Schächinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. *Crit Care Med* 2000;28:977-983.
- Schuetz P, Bretscher C, Bernasconi, et al. Overview of procalcitonin assays and pro-calcitonin-guided protocols for the management of patients with infections and sepsis. *Expert Rev Mol Diagn* 2017;17:593-601.
- Neeser O, Branche A, Mueller B, et al. How to: implement procalcitonin testing in my practice. *Clin Microbiol Infect* 2019;25:1226-1230.
- Schuetz P, Christ-Crain M, Thomann, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. *JAMA* 2009;302:1059-1066.
- Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. *Lancet Infect Dis* 2018;18:95-107.
- Odermatt J, Friedli N, Kutz A, et al. Effects of procalcitonin testing on antibiotic use and clinical outcomes in patients with upper respiratory tract infections. An individual patient data meta-analysis. *Clin Chem Lab Med* 2017;56:170-177.
- Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev* 2017;10:CD007498.
- Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. *Clin Infect Dis* 2012;55:651-662.
- Baer G, Baumann P, Buettcher M, et al. Procalcitonin guidance to reduce antibiotic treatment of lower respiratory tract infection in children and adolescents (Pro-PAED): a randomized controlled trial. *PLoS ONE* 2013;8:e68419.
- Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in 'real life': an international, multicenter poststudy survey (ProREAL). *Arch Intern Med* 2012;172:715-722.
- de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomized, controlled, open-label trial. *Lancet Infect Dis* 2016;16:819-827.
- Pepper D, Sun J, Rhee C, et al. Procalcitonin-guided anti-biotic discontinuation and mortality in critically ill adults: A systematic review and meta-analysis. *Chest* 2019;155:1109-1118.
- Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. *Crit Care* 2018;22:191.
- Lam SW, Bauer SR, Fowler R, et al. Systematic review and meta-analysis of procalcitonin-guidance versus usual care for antimicrobial management in critically ill patients: Focus on subgroups based on antibiotic initiation, cessation, or mixed strategies. *Crit Care Med* 2018;46:684-690.
- Iankova I, Thompson-Leduc P, Kirson, et al. Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: A systematic review and meta-analysis. *Crit Care Med* 2018;46:691-698.
- Heilmann E, Gregoriano C, Wirz Y, et al. (2020). Association of kidney function with effectiveness of procalcitonin-guided antibiotic treatment: a patient-level meta-analysis from randomized controlled trials. *Clin Chem Lab Med Epub ahead of print. PMID:32986609.*

# Elecsys BRAHMS PCT

- 34 Rello J, van Engelen TSR, Alp E, et al. Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect 2018;24:1264-1272.
- 35 Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections-summary. Clin Microbiol Infect 2011;17 Suppl 6:1-24.
- 36 Second WHO Model List of Essential In Vitro Diagnostics. 2019. Available from: [https://www.who.int/medical\\_devices/publications/Standalone\\_document\\_v8.pdf?ua=1](https://www.who.int/medical_devices/publications/Standalone_document_v8.pdf?ua=1). Accessed 28 January 2020.
- 37 Occupational Safety and Health Standards: Bloodborne pathogens. (29 CFR Part 1910.1030). Fed. Register.
- 38 Directive 2000/54/EC of the European Parliament and Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work.
- 39 Meisner M. Procalcitonin (PCT) – A new innovative infection parameter. Biochemical and clinical aspects. Thieme Stuttgart, New York 2000, ISBN: 3-13-105503-0.
- 40 Chiesa C, Panero A, Rossi N, et al. Reliability of Procalcitonin Concentrations for the Diagnosis of Sepsis in Critically ill neonates. Clin Infect Dis 1998;26:664-672.
- 41 Brunkhorst FM, Wegschneider K, Forycki ZF, et al. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med, 2000;26 Suppl 2:148-152.
- 42 American College of Chest Physicians/Society of Critical Care Medicine Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
- 43 Schuetz P, Raad I and Amin DN. Using procalcitonin-guided algorithms to improve antimicrobial therapy in ICU patients with respiratory infections and sepsis. Curr Opin Crit Care, 2013;19(5):453-460.
- 44 American College of Chest Physicians/Society of Critical Care Medicine Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
- 45 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

CONTENT
SYSTEM
REAGENT
CALIBRATOR
→
GTIN

Contents of kit

Analyzers/Instruments on which reagents can be used

Reagent

Calibrator

Volume for reconstitution

Global Trade Item Number

Rx only

For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

COBAS, NAVIFY, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2024, Roche Diagnostics



Roche Diagnostics GmbH  
Sandhofer Strasse 116  
68305 Mannheim, Germany  
[www.roche.com](http://www.roche.com)

+800 5505 6606



This product may not be used by purchaser to conduct any Point-of-Care testing including but not limited to any near patient testing on hospital wards and/or emergency departments and/or in doctor's offices and/or in any other locations outside private or public clinical laboratories. No general patent or other license of any kind other than this specific right of use from purchase is granted hereby.

For further information, please refer to the appropriate user guide or operator's manual for the analyzer concerned, the respective application sheets and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Reagent developed in collaboration with B-R-A-H-M-S GmbH.

B-R-A-H-M-S PCT is a registered trademark of Thermo Fisher Scientific Inc.

B · R · A · H · M · S

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

The Summary of Safety & Performance Report can be found here: <https://ec.europa.eu/tools/eudamed>

## Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see [navifyportal.roche.com](http://navifyportal.roche.com) for definition of symbols used):